18 June 2013
Keywords: acadia, acp-103, misses, ph, ii, endpoint, usa-based
Article | 12 December 2005
USA-based Acadia Pharmaceuticals says that its lead drug candidate ACP-103 failed to achieve a significant reduction of
haloperidol-induced akathisia, a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 December 2005
17 June 2013
© 2013 thepharmaletter.com